HRP20191285T1 - Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti - Google Patents

Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti Download PDF

Info

Publication number
HRP20191285T1
HRP20191285T1 HRP20191285TT HRP20191285T HRP20191285T1 HR P20191285 T1 HRP20191285 T1 HR P20191285T1 HR P20191285T T HRP20191285T T HR P20191285TT HR P20191285 T HRP20191285 T HR P20191285T HR P20191285 T1 HRP20191285 T1 HR P20191285T1
Authority
HR
Croatia
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical preparation
acceptable salt
formula
Prior art date
Application number
HRP20191285TT
Other languages
English (en)
Croatian (hr)
Inventor
Benoit Cardinal-David
Vincent S. Chan
Kassibla E. Dempah
Brian P. Enright
Rodger F. Henry
Raimundo Ho
Ye Huang
Alexander D. Huters
Russell C. Klix
Scott W. Krabbe
Philip R. Kym
Yanbin Lao
Xiaochun Lou
Sean E. MACKEY
Mark A. Matulenko
Peter T. Mayer
Christopher P. Miller
James Stambuli
Eric A. Voight
Zhi Wang
Geoff G. Zhang
Valentino J. Stella
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191285(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of HRP20191285T1 publication Critical patent/HRP20191285T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20191285TT 2014-10-21 2015-10-21 Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti HRP20191285T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
EP15791424.3A EP3209302B1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (1)

Publication Number Publication Date
HRP20191285T1 true HRP20191285T1 (hr) 2019-10-18

Family

ID=54478240

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191285TT HRP20191285T1 (hr) 2014-10-21 2015-10-21 Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti

Country Status (37)

Country Link
US (7) US9446059B2 (enExample)
EP (3) EP3209302B1 (enExample)
JP (6) JP6567049B2 (enExample)
KR (3) KR20240113982A (enExample)
CN (4) CN111362980B (enExample)
AR (1) AR102389A1 (enExample)
AU (4) AU2015335941B2 (enExample)
BR (1) BR112017008198B1 (enExample)
CA (1) CA2965379A1 (enExample)
CY (2) CY1121826T1 (enExample)
DK (1) DK3209302T3 (enExample)
ES (1) ES2739536T3 (enExample)
FI (1) FIC20230014I1 (enExample)
FR (1) FR23C1035I2 (enExample)
HR (1) HRP20191285T1 (enExample)
HU (2) HUE044115T2 (enExample)
IL (3) IL251829B (enExample)
LT (2) LT3209302T (enExample)
LU (1) LUC00304I2 (enExample)
MX (2) MX381069B (enExample)
MY (1) MY189519A (enExample)
NL (1) NL301224I2 (enExample)
NO (1) NO2023013I1 (enExample)
PH (1) PH12017500746B1 (enExample)
PL (1) PL3209302T3 (enExample)
PT (1) PT3209302T (enExample)
RS (1) RS58972B1 (enExample)
RU (2) RU2021103000A (enExample)
SA (1) SA521421115B1 (enExample)
SG (1) SG11201703170RA (enExample)
SI (1) SI3209302T1 (enExample)
SM (1) SMT201900376T1 (enExample)
TR (1) TR201908296T4 (enExample)
TW (2) TWI755257B (enExample)
UA (1) UA120437C2 (enExample)
WO (1) WO2016065019A1 (enExample)
ZA (1) ZA201702760B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3209302T3 (da) * 2014-10-21 2019-05-13 Abbvie Inc Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom
WO2017184871A1 (en) * 2016-04-20 2017-10-26 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
CA3028423A1 (en) * 2016-06-22 2017-12-28 Medchem Partners, Llc. Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
US10729710B2 (en) 2017-11-24 2020-08-04 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
MY203233A (en) 2018-09-13 2024-06-19 Univ Canberra Methods of inhibition
CA3117983A1 (en) * 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US12319710B2 (en) 2019-05-21 2025-06-03 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's diseases
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP3972600A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
DE69016688T2 (de) * 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
CA2309792A1 (en) * 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
KR20050027095A (ko) 2002-06-20 2005-03-17 닛폰 스이산 가부시키가이샤 프로드러그, 그 의약으로서의 사용 및 그 제법
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
CA2536175C (en) 2003-08-29 2013-05-28 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
JP2007509975A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン ギャバペンチン及びプレギャバリンの増加された吸収のための組成物及び投与形態物
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
BRPI0512970A (pt) 2004-07-06 2008-04-22 Abbott Lab prodrogas de inibidores da hiv protease
CN101365439B (zh) * 2005-12-05 2012-12-26 克塞诺波特公司 左旋多巴前体药物甲磺酸盐、其组合物及其用途
WO2007138086A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
WO2007144422A2 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
US7709527B2 (en) 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
MX2010008711A (es) * 2008-02-06 2011-05-03 Wockhardt Ltd Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
AU2010250766B2 (en) 2009-05-19 2015-04-09 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
NZ610911A (en) 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
AU2011337596B2 (en) 2010-12-02 2016-07-07 Ono Pharmaceutical Co., Ltd. Novel compound and medical use thereof
AU2011341316A1 (en) 2010-12-10 2013-07-04 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) * 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
JP6472391B2 (ja) 2013-03-13 2019-02-20 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ パーキンソン病の治療方法
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
DK3209302T3 (da) 2014-10-21 2019-05-13 Abbvie Inc Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
WO2017184871A1 (en) 2016-04-20 2017-10-26 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
US10730895B2 (en) 2020-08-04
CN107206013A (zh) 2017-09-26
NO2023013I1 (no) 2023-03-20
UA120437C2 (uk) 2019-12-10
AU2021201414A1 (en) 2021-03-25
TWI718999B (zh) 2021-02-21
RU2021103000A (ru) 2021-03-01
JP2017537066A (ja) 2017-12-14
JP2023174770A (ja) 2023-12-08
KR20170071599A (ko) 2017-06-23
JP2021183628A (ja) 2021-12-02
JP7688087B2 (ja) 2025-06-03
RU2017117413A (ru) 2018-11-26
AU2025238004A1 (en) 2025-10-16
US20220153765A1 (en) 2022-05-19
KR20230066484A (ko) 2023-05-15
TW202131931A (zh) 2021-09-01
AU2023210650A1 (en) 2023-08-24
CY2023010I1 (el) 2023-06-09
HUE044115T2 (hu) 2019-10-28
SA521421115B1 (ar) 2022-03-01
IL268885A (en) 2019-10-31
US20180079762A1 (en) 2018-03-22
KR102537018B1 (ko) 2023-05-30
CN111454290A (zh) 2020-07-28
JP6750076B2 (ja) 2020-09-02
EP3209302B1 (en) 2019-04-24
LUC00304I2 (enExample) 2025-09-22
RS58972B1 (sr) 2019-08-30
EP4186510A1 (en) 2023-05-31
JP6567049B2 (ja) 2019-08-28
NL301224I2 (nl) 2023-08-16
IL251829B (en) 2019-09-26
FR23C1035I2 (fr) 2025-04-18
JP6932227B2 (ja) 2021-09-08
CN111362980B (zh) 2022-10-18
AU2021201414B2 (en) 2023-05-11
US11091507B2 (en) 2021-08-17
RU2743347C2 (ru) 2021-02-17
NZ769153A (en) 2024-04-26
NL301224I1 (enExample) 2023-03-29
WO2016065019A1 (en) 2016-04-28
JP2019218356A (ja) 2019-12-26
IL268885B (en) 2020-08-31
HUS2300009I1 (hu) 2023-03-28
AU2015335941B2 (en) 2021-04-01
PT3209302T (pt) 2019-07-19
FIC20230014I1 (fi) 2023-03-31
LTPA2023519I1 (enExample) 2023-06-26
JP2025118978A (ja) 2025-08-13
TR201908296T4 (tr) 2019-06-21
BR112017008198B1 (pt) 2021-02-09
MY189519A (en) 2022-02-16
TW201630924A (zh) 2016-09-01
CY1121826T1 (el) 2020-07-31
AR102389A1 (es) 2017-02-22
LTC3209302I2 (enExample) 2025-10-10
JP2020189864A (ja) 2020-11-26
CY2023010I2 (el) 2023-06-09
TWI755257B (zh) 2022-02-11
MX2017005236A (es) 2017-07-26
AU2015335941A1 (en) 2017-05-04
NZ730996A (en) 2024-04-26
PH12017500746A1 (en) 2017-10-30
IL276493A (en) 2020-09-30
EP3569587A1 (en) 2019-11-20
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
PH12017500746B1 (en) 2021-12-15
PL3209302T3 (pl) 2019-10-31
US20230106081A1 (en) 2023-04-06
SMT201900376T1 (it) 2019-09-09
CA2965379A1 (en) 2016-04-28
US20160106765A1 (en) 2016-04-21
RU2017117413A3 (enExample) 2019-05-30
MX393568B (es) 2025-03-24
IL251829A0 (en) 2017-06-29
CN111494395A (zh) 2020-08-07
CN111362980A (zh) 2020-07-03
SG11201703170RA (en) 2017-05-30
US10174061B2 (en) 2019-01-08
ZA201702760B (en) 2022-05-25
EP3209302A1 (en) 2017-08-30
CN111494395B (zh) 2024-06-21
LT3209302T (lt) 2019-06-10
US9446059B2 (en) 2016-09-20
US20160362431A1 (en) 2016-12-15
KR20240113982A (ko) 2024-07-23
SI3209302T1 (sl) 2019-06-28
DK3209302T3 (da) 2019-05-13
CN111454290B (zh) 2022-12-23
US20190375770A1 (en) 2019-12-12
US20200262852A1 (en) 2020-08-20
MX381069B (es) 2025-03-12
MX2021003840A (es) 2022-06-30
ES2739536T3 (es) 2020-01-31

Similar Documents

Publication Publication Date Title
HRP20191285T1 (hr) Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
HRP20201883T1 (hr) Oralne i injekcijske formulacije tetraciklinskih spojeva
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX389600B (es) Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
RU2016138577A (ru) Жидкая фармцевтическая композиция
RU2015145997A (ru) Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
ME02474B (me) Terapijski režimi
FI3666258T3 (fi) Menetelmä prader-willin oireyhtymän hoitamiseksi
ZA202000028B (en) Use of vibegron to treat overactive bladder
JP2016505050A5 (enExample)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
MY193963A (en) Composition for treating joint diseases and kit containing same
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
HRP20200031T1 (hr) Uporaba cerebrolizina
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
BR112017025527A2 (pt) preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe.
JP2019535830A5 (enExample)